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Abstract
Background: Fos-related antigen 1 (FRA-1) is an immediate early gene encoding a member of AP-
1 family of transcription factors involved in cell proliferation, differentiation, apoptosis, and other
biological processes. fra-1 gene overexpression has an important role in the process of cellular
transformation, and our previous studies suggest FRA-1 protein detection as a useful tool for the
diagnosis of thyroid neoplasias. Here we investigate the expression of the FRA-1 protein in benign
and malignant breast tissues by immunohistochemistry, Western blot, RT-PCR and qPCR analysis,
to evaluate its possible help in the diagnosis and prognosis of breast neoplastic diseases.
Methods: We investigate the expression of the FRA-1 protein in 70 breast carcinomas and 30
benign breast diseases by immunohistochemistry, Western blot, RT-PCR and qPCR analysis.
Results: FRA-1 protein was present in all of the carcinoma samples with an intense staining in the
nucleus. Positive staining was also found in most of fibroadenomas, but in this case the staining was
present both in the nucleus and cytoplasm, and the number of positive cells was lower than in
carcinomas. Similar results were obtained from the analysis of breast hyperplasias, with no
differences in FRA-1 expression level between typical and atypical breast lesions; however the FRA-
1 protein localization is mainly nuclear in the atypical hyperplasias. In situ breast carcinomas showed
a pattern of FRA-1 protein expression very similar to that observed in atypical hyperplasias.
Conversely, no FRA-1 protein was detectable in 6 normal breast tissue samples used as controls.
RT-PCR and qPCR analysis confirmed these results. Similar results were obtained analysing FRA-1
expression in fine needle aspiration biopsy (FNAB) samples.
Conclusion:  The data shown here suggest that FRA-1 expression, including its intracellular
localization, may be considered a useful marker for hyperplastic and neoplastic proliferative breast
disorders.
Published: 25 January 2007
BMC Cancer 2007, 7:17 doi:10.1186/1471-2407-7-17
Received: 9 August 2006
Accepted: 25 January 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/17
© 2007 Chiappetta et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
Page 2 of 11
(page number not for citation purposes)
Background
The transcription factor complex AP-1 plays a central role
in regulating gene transcription in several biological proc-
esses [1]. It is constituted of a great variety of dimers com-
posed of members of the Fos, Jun, and ATF families of
proteins. While the Fos proteins (c-Fos, FosB, Fra-1, Fra-2)
can only heterodimerise with members of the Jun family,
the Jun proteins (c-Jun, JunB, JunD) can both
homodimerise and heterodimerise with Fos and ATF fam-
ilies members to form transcriptionally active complexes
[2,3]. Several data show that modifications in AP-1 activ-
ity are correlated with cell transformation. In fact, cellular
transformation and malignancy induced by ras  genes
require c-jun, and fra-2/-c-jun heterodimers that play a cru-
cial role in chicken fibroblast transformation [4,5]. In par-
ticular, the induction of fra-1 seems to have a pivotal role
in the process of cell transformation and in the carcino-
genesis. Indeed, a) fra-1 exhibits oncogenic potential: its
over-expression in rat fibroblasts stimulates anchorage-
independent growth in absence of clear morphological
transformation [6]; b) the inhibition of FRA-1 protein
synthesis by stable transfection with a fra-1 antisense con-
struct significantly reduces the malignant phenotype of
the transformed thyroid cells [7]; c) FRA-1 induces mor-
phological transformation and increases in vitro invasive-
ness and motility of epithelioid adenocarcinoma cells [8];
d) transfection with a dominant-negative fra-1 construct
reverts the transformed phenotype of mesothelioma cells,
inhibiting their anchorage-independent growth in soft
agar [9]; e) ectopic co-expression of c-jun  and  fra-1  in
NIH3T3 fibroblasts leads to a transformed phenotype
[10]. High Fra-1 expression is associated with a more
malignant cell phenotype, and suggesting that Fra-1 could
have a pivotal role in breast cancer progression [11].
Consistently with this critical role of FRA-1 in cell trans-
formation, an increased FRA-1 expression in neoplastic
tissues has been frequently reported. In fact, a significant
increase of FRA-1 protein levels was detected in all onco-
gene transformed rat thyroid cell lines, and also in human
thyroid carcinoma cell lines and tissues [12]. Differential
gene expression in non-malignant and malignant
nasopharyngeal epithelial (NPE) cells, using a cDNA array
hybridization method, has evidenced fra-1  expression
only in the malignant cells [13]. Equally, the transcrip-
tional profile of rat pancreatic carcinoma cell lines BSp73-
AS (non-metastatic) and BSp73-ASML (highly metastatic)
has revealed FRA-1 expression only in the metastatic cells,
supporting a main role of fra-1 in the invasion process
[14]. This seems to be confirmed by the silencing of fra-1
gene, showing that the induction of CD44 and c-met is
causally linked to fra-1 expression, then connecting fra-1
with genes governing cell motility and invasion in mes-
othelioma [15].
In breast carcinomas, the analysis of the AP-1 family
members (c-jun, junB, junD and c-fos, fosB, fra1 and fra2)
revealed association of fosB expression with a well-differ-
entiated receptor-positive tumor phenotype, whereas the
expression of fra-1 showed significant negative correlation
with fosB expression, as well as with estrogen-receptor sta-
tus and differentiation [16]. Moreover, cDNA hybridiza-
tion arrays to analyze the gene expression profiles (GEPs)
of nine weakly invasive and four highly invasive breast
carcinoma cell lines revealed fra-1 expression only in the
highly invasive cell lines [17]. Therefore, also these results
seem to support a critical role of fra-1 in breast carcino-
mas, likely in the progression step. On this basis, it was
also conceived a vaccination versus the FRA-1 protein to
prevent breast carcinomas. Indeed, the growth of primary
subcutaneous tumor and dissemination of pulmonary
metastases, induced by the inoculation of D2F2 murine
breast carcinoma cell line, were markedly suppressed by a
vaccine carried by attenuated Salmonella typhimurium
and encoding murine FRA-1 [18].
Therefore, the aim of our study was to investigate whether
evaluation of FRA-1 protein expression in breast neopla-
sias using different technical approaches might be a useful
tool in the diagnosis and prognosis of human breast car-
cinomas. In the present study, we show that no fra-1
expression is detectable in normal breast tissue. Con-
versely, FRA-1 protein was abundant in all of the carci-
noma samples with an intense staining in the nucleus.
Positive staining was also found in fibroadenomas and
hyperplasias without atypia, but in these cases the stain-
ing was both in the nucleus and cytoplasm, and the
number of positive cells was lower than carcinomas. Con-
versely, atypical hyperplasias and in situ ductal carcino-
mas showed positivity restricted mainly to the nuclei.
Analogous results were obtained analysing FRA-1 expres-
sion in fine needle aspiration biopsy (FNAB) samples.
Methods
Tissue samples
Tissue sections for immunohistochemistry [106 breast tis-
sue specimens, constituted by 6 normal breast tissues cor-
responding to a macroscopically healthy region distinct
from neoplastic lesions, 15 hyperplastic lesions (6 with
atypical lesions), 15 fibroadenomas, 10 in situ ductal car-
cinomas, 40 ductal carcinomas and 20 lobular carcino-
mas] were obtained from routinely processed paraffin-
embedded samples of breast neoplasias resected from the
National Institute of Cancer G. Pascale foundation in
Naples, Italy. Institutional ethical approval and informed
consent will given by the patients undergoing surgery for
breast cancer. The criteria for inclusion in the study were
that the routinely processed paraffin blocks were suitable
for immunohistochemistry, and adequate clinical infor-
mation. The clinical and histological characteristics of theBMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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60 carcinomas were: 51 patients (85%) presented with
stage I and 9 patients (15%) with stage II tumours. 70% of
tumors were hormonal receptor-positive and 30% were
hormonal receptor-negative. Elston-Ellis grade deter-
mined at diagnosis was I in 12 patients (20%), II in 38
(63%) and III in10 patients (17%).
Immunohistochemistry
5–6-μm-thick paraffin sections were deparaffinized and
analysed as previously described [19]. Slides were incu-
bated with the primary antibodies diluted 1:100 in PBS
and then with biotinylated goat antirabbit IgG for 20 min
(Vectostain ABC kits; Vector Laboratories), followed from
the incubation with premixed reagent ABC (Vector) for 20
min. The immunostaining was performed by incubating
slides in diaminobenzidine (Dako) solution containing
0.06 mM diaminobenzidine and 2 mM hydrogen perox-
ide in 0.05% PBS (pH 7.6) for 5 min. After chromogen
development, slides were washed, dehydrated with alco-
hol and xylene, and mounted with coverslips using a per-
manent mounting medium (Permount). Micrographs
were taken on Kodak Ektachrome film with a photo Zeiss
system.
Immunohistochemycal analysis of breast Fine Needle 
Aspiration Biopsies (FNAB)
The FNABs were performed at the "Istituto Nazionale dei
Tumori di Napoli" in Italy, according to established pro-
cedures using a 25-gauge needle attached to a 20 ml
syringe in a plastic syringe holder. Alcohol-fixed and air-
dried smears were immediately immunostained using the
same antibody as described above. Samples were
obtained from 10 patients with breast neoplasias who
subsequently underwent surgery because examination of
the FNAB yielded cytologic diagnoses suspicious for can-
cer. Normal breast cells obtained after FNAB of the nor-
mal adjacent tissues of the patients were used as controls.
The antibodies were made in our laboratory [20]. They are
specific for FRA-1 and non-cross-reactive with the other
members of the Fos family. The immunostained samples
were blindly read by three independent individuals (G.C.,
M.D.B. and G.B.).
Western blot
Immunoblottings were performed according to standard
procedure, and previously described [12]. Anti-FRA-1
antibodies were previously described [20], and anti-tubu-
lin was from Santa Cruz Biotechnology. Protein extract
from a positive cell line (MDA-MB231) was loaded in one
well as control for comparable exposition of chemilumi-
nescent membranes.
RT-PCR analysis
RNA was extracted from paraffin-embedded blocks on 40
cases analyzed in parallel for FRA-1 expression by immu-
nohistochemistry, as previously described [18]. One μg of
total RNA, digested with Dnase, was reverse transcribed
using random exanucleotides as primers (2.5 μM) and 50
units of MuLV Reverse transcriptase, and subsequent PCR
amplification was performed as mentioned here after.
Two hundred ng of cDNA were amplified in a 25 μl reac-
tion mixture containing 1.25 unit Taq DNA in polymerase
buffer, 0.2 mM deoxynucleotide triphosphate, 1.5 mM
MgCl2, 1.30 μM of each primer (Applied Biosystem-
Roche). The PCR amplification was performed for 40
cycles (94°C for 30 s, 54°C for 30 s, and 72°C for 30 s).
The specific primers for FRA-1 were: forward 5'-cgaaggcctt-
gtgaacagat-3', and reverse 5'-ctgcagcccagatttctcat-3'; corre-
sponding to the nucleotides 315–335 and 459–478,
respectively. Amplification of contaminating genomic
DNA was excluded by control experiments in absence of
reverse transcriptase. Glyceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) expression was used as internal con-
trol [12]. A PhosphorImager screen was briefly exposed to
the membranes, and the screen was then scanned on a
Molecular Dynamics PhosphorImager. The images
recorded by the PhosphorImager were analyzed by vol-
ume integration with the ImageQuant software.
Quantitative PCR
Selection of primers and probes
To design a qPCR assay, we used a Human ProbeLibray™
system (Exiqon, Denmark) [21,22]. The free ProbeFinder
assay design software is an integrated part of the package.
All fluorigenic probes were dual-labeled with FAM at 5'
end and with a black quencer at the 3' end. We chose the
best probe and primers pair to amplify a fragment for real-
time PCR of fra-1 mRNA, entering its accession number
(X16707) on the assay design page of the ProbeFinder
software. Based on these data, the software provided us
various solutions. We chose an amplicon of 119 nucle-
otides scattered among first and second exon. The number
of probe was "human 27" (according to the numbering of
Exiquon's Human ProbeLibry kit), and the primer
sequences were: FRA-1 forward 5'-gggcatgttccgagacttc-3';
FRA-1 reverse 5'-gcaccaggtggaacttctg-3'. The same proce-
dure was used to choose both probe and primers for
housekeeping gene glucose 6-phosphate dehydrogenase
g6pd, accession number X03674. The ProbeFinder pro-
vided us various solutions for g6pd, as well as fra-1 tran-
script. We opted for an amplicon of 106 nucleotides
scattered among third and fourth exon. The number of
probe was "human 05", and the primer sequences were:
g6pd forward 5'-acagagtgagcccttcttcaa-3'; g6pd reverse 5'-
ggaggctgcatcatcgtact-3'.
cDNA preparation
1 μg of total RNA of each sample was reverse-transcribed
with the RNA PCR Core kit (Applied Biosystems, Roche)BMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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using random hexamer primers according to the manufac-
turer's instructions.
Results
Immunohistochemical analysis of FRA-1 expression in 
breast neoplastic samples
The immunohistochemical technique was chosen for
FRA-1 protein analysis because it allows a rapid and sen-
sitive screening of breast pathological tissues and is ame-
nable to regular use as a routine diagnostic test. We used
antibodies raised against a FRA-1 specific peptide gener-
ated in our laboratory [20], to analyse 106 breast tissues,
including 6 normal tissues, 15 dysplasias (6 with atypical
lesions), 15 fibroadenomas, 10 in situ ductal carcinomas,
40 ductal carcinomas and 20 lobular carcinomas. The
results of the immunohistochemical study of breast spec-
imens are summarized in Table 1. Most of the breast car-
cinoma samples (92%) showed a strong nuclear
immunoreactivity in the majority of the cells. No cyto-
plasmic staining was observed. Similar results were
obtained when in situ ductal carcinomas were analyzed,
even though the immunoreactivity was restricted to a
reduced number of cells in comparison to the carcinoma
samples and a weak cytoplasmic staining is present. As far
as breast hyperplasias are concerned, we observed no dif-
ferent FRA-1 protein levels between atypical and typical
breast hyperplasias, but the FRA-1 immunolocalization
was essentially present in the nuclei in the atypical lesions,
whereas the typical lesions showed a mainly cytoplasmic
staining. Conversely, no staining at all was observed in six
normal breast tissues. Positive staining was also found in
benign fibroadenomas, but, in this case, the staining was
present both in the nucleus and cytoplasm, and these
samples showed a weaker staining in comparison to the
breast carcinomas. In the Figures 1 and 2, we show some
representative immunohistochemical analyses. No posi-
tive signal is detected in normal breast tissue (Figure 1A),
whereas an intense nuclear staining is clearly observed in
a ductal carcinoma (Figure 1B). The specificity of the anti-
bodies versus the FRA-1 protein was also evaluated. In
fact, for each case, sections were stained without the pri-
mary antibody. In all cases these controls were negative
(Figure 1C). Equally, no staining was also observed when
the neoplastic tissues were analyzed after that the FRA-1
specific antibodies have been pre-incubated with the FRA-
1 control peptide (Figure 1D). Figures 2A and 2B show the
immunostaining of a positive typical hyperplasia and a
positive fibroadenoma, respectively: a minority of the
cells show nuclear immunoreactivity that appeared asso-
ciated with a constant, cytoplasmic staining. In the case of
the  in situ ductal breast carcinomas, the staining was
always restricted to the nucleus, but it was not detected in
all the cells (Figure 2E). Figures 2C and 2D show the
immunostaining of an atypical hyperplasia at two differ-
ent magnifications: the FRA-1 immunoreactivity is
present in the majority of the nuclei and a cytoplasmic
staining is present. This pattern of FRA-1 protein expres-
sion and localization is very similar to that observed in the
breast  in situ ductal carcinomas. Figure 2F show the
immunostaining of a lobular breast carcinoma with an
intense nuclear staining in all the malignant cells.
Fra-1 overexpression in breast tumour samples
In a limited number of samples ((2 normal breast tissues,
2 hyperplasias, and 4 ductal carcinomas), FRA-1 protein
expression was also evaluated by Western blot analysis,
that essentially confirmed the immunohistochemical
data. In fact, as it is shown in the Figure 3, a FRA-1 specific
single band with apparent molecular weight of 38,000
kDA was present in the carcinoma samples (lanes 6, 7, 8,
9) but not in the normal breast tissues (lanes 2, 3). Breast
hyperplastic lesions showed FRA-1 protein expression but
it was lower than that found in the carcinoma samples
(lanes 4, 5). Specific FRA-1 protein bands were identified
by apparent molecular weight relative to standard pro-
teins (prestained protein ladder, Invitrogen). The pres-
ence of a single band in all samples would suggest that
Fra-1 phosphorylation status does not change.
Semiquantitative and quantitative RT-PCR analysis
To quantitate the levels of the fra-1 gene expression and
validate the immunohistochemical data, we also analyzed
26 samples (2 normal breast tissues, 8 hyperplasias, 6
fibroadenomas, and 10 ductal carcinomas) for the specific
fra-1 mRNA levels by a semiquantitative RT-PCR assay.
The results are consistent with the immunohistochemical
findings. A representative RT-PCR assay is shown in Figure
4. The normal breast tissue samples were negative for fra-
1 gene expression (lane 1). Three hyperplasias (lanes 2, 3
and 4) and three fibroadenomas (lanes 5, 6 and 7) were
positive for fra-1 expression, at levels comparable among
them. All of the malignant tumours showed a significant
fra-1 expression (from lane 8 to 12). Gapdh amplification
was used as internal control.
To better evaluate the differences in fra-1 gene expression
in the different breast samples, we performed a quantita-
tive RT-PCR assay. To evaluate gene expression level, we
used the ΔCt. For each sample, fra-1 Ct value was sub-
tracted from g6pd Ct value (Ctfra-1-Ctg6pd), used to normal-
ize the amount of cDNA. In Figure 5, we compared the
ΔCt values of fibroadenoma, hyperplasia, carcinoma and
normal breast samples. In breast carcinomas fra-1 Δct val-
ues (5.79–10.58) was lower because fra-1 mRNA could be
detected at a number of cycles a little higher than that
occurring for g6pd amplification. In fibroadenomas and
hyperplasias the ΔCt values (11.91–15.10) were between
the ΔCt of normal breast and ΔCt of carcinoma samples.
The result of t-test (p-value = 0,00032) between ΔCt val-
ues of carcinomas group and ΔCt values of fibroadenomasBMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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and hyperplasias group indicated that there is a significant
difference of fra-1 mRNA level between these tumor histo-
types.
Analysis of fra-1 gene expression in breast fine needle 
aspiration biopsy
Fine needle aspiration biopsy (FNAB) has a critical role in
the preoperative diagnostic analysis of breast neoplasias.
To evaluate the applicability of fra-1 gene expression anal-
ysis to FNABs samples, we studied 10 cases of breast carci-
nomas and 4 normal breast samples obtained after FNAB
of the normal adjacent tissues. In one patient (lane 3), we
also obtained hyperplastic cells after FNAB from a hyper-
plastic region adjacent to the carcinoma. The cytological
specimens were analyzed for fra-1 expression by immuno-
histochemistry and RT-PCR. The results are shown in
Table 2 and Figure 6. Immunohistochemistry showed
nuclear staining in the carcinoma samples (Panel B), but
not in the normal tissue (Panel A). No staining was
observed when the FNAB deriving from carcinoma was
incubated in the absence of the primary antibody (Panel
C). Equally, RT-PCR analysis (Panel D) revealed fra-1 gene
expression in the carcinoma samples (lanes 3, 4, 5) but
not in the normal breast tissue (lane 1) deriving from the
same patient shown in lane 3. fra-1 expression was at a sig-
nificant lower level in the hyperplastic region (lane 2) of
the same patient shown in lane 3 in comparison to the
carcinoma samples.
Discussion
Breast cancer is the most common cancer and the second
leading cause of cancer mortality in women, since epide-
miologic data suggest that one in every eight women will
suffer from breast carcinoma [23]. Breast neoplastic dis-
Immunohistochemical analysis of FRA-1 protein in breast tissues Figure 1
Immunohistochemical analysis of FRA-1 protein in breast tissues. Immunostaining of a normal breast tissue (100 ×) 
(A) and of a ductal carcinoma (200 ×) (B). The same ductal carcinoma was immunostained in the absence of the primary anti-
body (200 ×) (C), or with the FRA-1 antibodies pre-incubated with the peptide against which the antibodies were raised (200 
×) (D).BMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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Immunohistochemical analysis of FRA-1 in benign and malignant breast tissues Figure 2
Immunohistochemical analysis of FRA-1 in benign and malignant breast tissues. Paraffin sections from hyperlastic 
and neoplasic breast tissues were analyzed by immunohistochemistry using antibodies raised against a specific FRA-1 pep-
tide.A) Nuclear and cytoplasmic staining in a typical breast hyperplasia (200 ×). B) Immunostaining of a breast fibroadenoma 
(200 ×) showing nuclear and cytoplasmic staining. C) and D) Immunostaining of an atypical hyperplasia at two different magni-
fication (100 ×) and (200 ×) respectively: the staining is present in the majority of the nuclei and is weakly present in the cyto-
plasm. E) Immunostaining of a ductal in situ breast carcinoma (400 ×): the immunostaining is restricted to the nucleus and 
weakly present in the cytoplasm, but it is not present in all the cells. F) Immunostaining of a lobular carcinoma (400 ×): the 
immunostaining is restricted to the nucleus, and is present in all malignant cells.BMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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eases range from benign fibroadenoma to very aggressive
undifferentiated carcinoma. Growth factors and their
receptors, intracellular molecules, regulators of cell
cycling, and proteases, have all been shown to be altered
in sporadic breast cancer [24], and c-Erb-B2 and HMGA1
overexpression and loss of estrogen receptors correlate
with a poor prognosis [25].
Our aim was to verify whether FRA-1 protein detection
might be useful in the diagnosis and prognosis of human
Analysis of FRA-1 protein expression by western blot Figure 3
Analysis of FRA-1 protein expression by western blot. The imunoblotting analysis was performed on extracted proteins 
(20 μg/lane) in MDA-MB231 cells and in a limited number of breast samples, from normal, dysplastic and neoplastic breast tis-
sues. Sources of the proteins: lane 1: MDA-MB231 cells; lanes 2–3: normal breast tissues; lanes 4–5: breast dysplastic lesions; 
lanes 6–9: breast cancer tissues.
Table 1: FRA-1 protein expression and localization in normal and neoplastic breast tissues by immunohistochemistry.
FRA-1 staining score* N(%) FRA-1 localization**
Histological type 0 1+ 2+ 3+ 4+ N C N/C
Normal breast tissues (N = 6) 6 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 0 0
Fibroadenomas (N = 15) 0 (0) 2(13) 13(87) 0(0) 0(0) 2 11 2
Typical ductal hyperplasias (N = 9) 0 (0) 3 (33) 5 (56) 1 (11) 0 (0) 1 2 6
Atypical ductal hyperplasias (N = 6) 0 (0) 1 (17) 3 (50) 2 (33) 0 (0) 4 1 1
In situ ductal carcinomas (N = 10) 0 (0) 1 (10) 7 (70) 2 (20) 0 (0) 6 1 2
Ductal + Lobular carcinomas (N = 60) 0 (0) 0 (0) (0) 5 (8) 55(92) 52(0) 0 (0) 8
*FRA-1 staining score was: 0, no. positive cells; +, positive cells; 1+, < 10% of positive cells; 2+, 11–50% of positive cells; 3+, 51–75% of positive 
cells; 4+, 76–100% positive cells. N, number of cases.
**N=Nuclear, C = Cytoplasmic, N/C = nuclear and cytoplasmic stainingBMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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breast neoplasias. The rationale for this study derives from
several studies demonstrating a critical role of AP-1 com-
plex, and, in particular, of one of its members FRA-1 in
cell transformation, since FRA-1 promotes cell motility by
inactivating beta-1 integrin and keeping RhoA activity low
[26]. Moreover, recent data demonstrate that fra-1 expres-
ΔCt Figure 5
ΔCt, difference between Ct value of fra-1 mRNA and Ct value of g6pd mRNA (ΔCt =Ctfra-1-Ctg6pd). 
F, fibroadenoma; D, displasia; C, carcinoma.  
RT-PCR analysis of the fra-1 gene expression in paraffin-embedded tissues Figure 4
RT-PCR analysis of the fra-1 gene expression in paraffin-embedded tissues. The mRNA was extracted from paraffin-
embedded tissues and amplified by RT-PCR using fra-1 specific primers as specified under "Material and Methods". The cDNAs 
were co-amplified with gapdh gene as an internal control. Sources of RNA: lane 1, normal breast tissue; lanes 2–4, breast dys-
plastic lesions; lanes 5–7, breast fibroadenomas; lanes 8–12, breast carcinomas; lane 13: water control. Molecular markers are 
indicated.BMC Cancer 2007, 7:17 http://www.biomedcentral.com/1471-2407/7/17
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sion is controlled by different thresholds of ERK activity,
that is frequently increased in cancer. In fact, a basal ERK
activity is required to induce transcription of the fra-1
gene, but additional higher levels of activity stabilize fra-1
against proteasome-dependent degradation [27]. In our
study, we found that fra-1 expression, evaluated by immu-
nohistochemistry, western blot and semiquantitative and
quantitative RT-PCR, started to become detectable in
fibroadenomas and hyperplastic stage and strongly detect-
able in carcinoma samples. Conversely, breast normal tis-
sues did not show any detectable expression of fra-1. The
gene expression level evaluated by qPCR indicated more
than 40-fold difference between carcinomas group and
fibroadenomas and hyperplastic group. In fact, the expres-
sion was higher and concerning the vast majority of the
cells, and exclusively nuclear in the cancer tissues, whereas
breast fibroadenomas and typical hyperplasias showed a
weaker expression, not present in the majority of the cells,
with a constant cytoplasmic staining. Concerning breast
atypical hyperplasias, we did not observe different levels
of FRA-1 protein expression compared the typical ones,
but the FRA-1 immunolocalization was essentially present
in the nuclei in the atypical lesions and a weakly cytoplas-
mic staining was present. A similar behavior was observed
in "in situ" ductal carcinomas. In fact, the staining was
restricted to the nucleus, but the number of positive cells
was lower compared to the carcinomas samples. It is likely
that this different behaviour of FRA-1 in these samples
might be dependent on different genetic alterations. How-
ever, in contrast with previously published data showing
a negative correlation between fra-1 expression and hor-
mone receptor status in mammary carcinoma cell lines,
no significant differences were observed in the FRA-1
expression among different morphological grading of the
breast carcinoma samples and other prognostic indicators
of breast carcinomas (ER and PgR receptors, Ki67 and
ERB-B2), Therefore, its detection does not seem to have
any prognostic value. It is more likely that the different
immunolocalization and gene expression level of FRA-1
might represent a useful tool for differentiating breast car-
cinomas for their aggressiveness.
Conclusion
It is noteworthy that the analysis of FNAB samples by
immunohistochemistry and RT-PCR confirms the results
obtained by the same techniques on the surgically
removed tissues, suggesting that a preoperative evaluation
of FRA-1 expression might be a useful tool in the diagno-
sis of breast dysplastic and/or neoplastic lesions. Moreo-
ver, the restriction of fra-1 expression to breast neoplastic
tissues together with the previous results, indicating a crit-
ical role of fra-1 in the process of carcinogenesis, makes
the FRA-1 protein as an excellent target for cancer therapy.
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